Biogenic Nanosilver against Multidrug-Resistant Bacteria (MDRB)

Author(s)

Barros, Caio H. N. ^{[1, 2]} ; Fulaz, Stephanie ^{[1, 2]} ; Stanisic, Danijela ^[1] ; Tasic, Ljubica ^[1]

Affiliation

^[1] Univ Estadual Campinas, Inst Chem, Biol Chem Lab, BR-13083970 Campinas, SP - Brazil

^[2] Univ Coll Dublin, Sch Bioproc & Chem Engn, Dublin D04 V1W8 - Ireland

• Document type: Review article
• Source: ANTIBIOTICS-BASEL; v. 7, n. 3 SEP 2018.
• Web of Science Citations: 11

Abstract

Multidrug-resistant bacteria (MDRB) are extremely dangerous and bring a serious threat to health care systems as they can survive an attack from almost any drug. The bacteria's adaptive way of living with the use of antimicrobials and antibiotics caused them to modify and prevail in hostile conditions by creating resistance to known antibiotics or their combinations. The emergence of nanomaterials as new antimicrobials introduces a new paradigm for antibiotic use in various fields. For example, silver nanoparticles (AgNPs) are the oldest nanomaterial used for bactericide and bacteriostatic purposes. However, for just a few decades these have been produced in a biogenic or bio-based fashion. This review brings the latest reports on biogenic AgNPs in the combat against MDRB. Some antimicrobial mechanisms and possible silver resistance traits acquired by bacteria are also presented. Hopefully, novel AgNPs-containing products might be designed against MDR bacterial infections. (AU)

• FAPESP's process: 15/12534-5 - Study on the supramolecular interactions in Silver Nanoparticles and their antimicrobial activity
• Grantee: Caio Henrique Nasi de Barros
• Support Opportunities: Scholarships in Brazil - Master
• FAPESP's process: 14/50867-3 - INCT 2014: National Institute of Science and Technology in Bioanalysis
• Grantee: Marco Aurelio Zezzi Arruda
• Support Opportunities: Research Projects - Thematic Grants